Latest News
Fenebrutinib Approval: When Could the FDA Decide on Roche’s MS Drug?
Fenebrutinib approval is now under US priority review, but Roche has not said when the FDA will decide. The company announced on 30 September 2026 that the agency had accepted its new drug application. The filing covers relapsing multiple sclerosis (RMS) and primary...
Latest News
Roche Backs Lean Mass Preservation With $2.3bn Hanmi Obesity Deal
Roche has placed a fresh bet on lean mass preservation, the most contested new frontier in obesity drug development. On 24 August 2026, its Genentech unit licensed an experimental candidate from South Korea’s Hanmi Pharmaceutical. The drug, HM17321, is designed to...
How Sustainability Can Become a Competitive Advantage in Biomanufacturing
Sustainability has become an expectation across the life sciences industry. Regulations are evolving, customers expect more from suppliers, and companies are making increasingly ambitious environmental commitments. Compliance has helped create a common baseline for...
Obesity Drug News: GLP-1 Readouts and Approval Watch
Last updated 25 October 2026 This page is the running record of obesity drug news at Life Science Daily News. It tracks what moved in the obesity and GLP-1 pipeline each month. Entries cover trial readouts, regulatory filings, approvals and label expansions. How this...
Creative Biolabs’ CAR Engineering: Moving Cell Programming Inside the Body
CAR cell therapy has demonstrated that immune cells can be genetically programmed to recognize and attack disease-associated targets. Yet conventional CAR-T therapy generally depends on an elaborate ex vivo workflow involving cell collection, genetic modification,...
Join The Future Of Life Sciences Media
In a world overflowing with information, LifeScienceDaily.news stands apart as the dedicated space where life sciences professionals share what’s new, what’s next, and why it matters, all in real time.
Don’t wait for the media to pick up your story. Be the media.
Trending
More News
Astatine-211: The Alpha-Emitter Gaining Momentum in Targeted Radiotherapy
Astatine, the heaviest halogen and the rarest naturally occurring element, has long been a scientific curiosity. Among its many isotopes, ²¹¹At has emerged over the past decade as a frontrunner in the quest to harness alpha particles for highly targeted radiotherapy....
Life Science Development in Singapore: A Rising Global Powerhouse
Singapore has rapidly transformed into one of the world’s most advanced and influential life science hubs. Over the past two decades, the city-state has combined strategic investment, world-class infrastructure, and a thriving innovation ecosystem to position itself...
Halozyme Granted Injunction Against Merck in Keytruda Patent Case
A German court has granted Halozyme a preliminary injunction that halts the sale of the subcutaneous version of Keytruda in Germany, marking a significant legal win in the companies’ high stakes patent dispute. The decision could complicate Merck’s plans for the...
Pharma 5.0: The Future of Human-Centric, Intelligent, Sustainable Medicine
As the pharmaceutical industry undergoes rapid transformation, a new paradigm is taking shape. Known as Pharma 5.0, it represents more than an upgrade in technology, it is a fundamental shift toward human-centric innovation, sustainable manufacturing, and intelligent...
Pharvaris Announces Positive Phase 3 Results for Deucrictibant
Pharvaris Announces Positive Phase 3 Results for Deucrictibant as On Demand HAE Treatment Pharvaris has announced positive topline data from its global Phase 3 RAPIDe 3 study, confirming that the oral bradykinin B2 receptor antagonist deucrictibant shows strong...
AI & Cloud Enabled R&D and Clinical Operations Surge in Life Sciences
Digital transformation is accelerating across the life sciences sector as more organisations adopt AI driven platforms and cloud computing to speed up drug discovery, streamline clinical trials and optimise operations. A recent industry overview from BioSpace...
Autolus CAR-T Offers Hope to Adults with Aggressive Blood Cancer
The National Institute for Health and Care Excellence (NICE) has published final draft guidance recommending a novel, next-generation chimeric antigen receptor T-cell (CAR-T) therapy for use in the National Health Service (NHS). This landmark decision is set to...
Otsuka Wins Approval for Novel Rare Kidney Drug
Otsuka Gains Approval for First of Its Kind Treatment Against Rare Kidney Disease In a significant milestone for kidney disease care, Otsuka Pharmaceutical has received accelerated approval from the US Food and Drug Administration for a new therapy for Immunoglobulin...
US and UK Agree Zero Tariffs Deal on Pharmaceuticals
US and UK Agree Zero Tariffs Deal on Pharmaceuticals: What It Means for Patients, Innovation and Global Pharma Trade The United States and the United Kingdom have reached a landmark trade agreement that eliminates tariffs on UK-origin pharmaceuticals, active...
Hot Topic to Watch in China Life Sciences: Data Exclusivity & IP Reforms
China’s life sciences sector is poised for a potential regulatory shake-up this week, as stakeholders await clarity on data exclusivity and intellectual property (IP) protection reforms. Earlier this year, the National Medical Products Administration (NMPA) released a...
A Milestone in Rare Disease Genomics
Why popEVE Matters Interpreting missense variants has long been one of the most persistent challenges in clinical genetics. These single–amino-acid substitutions can subtly alter protein structure or function, yet their effects are often context-dependent and...
Brain Cell Communication at the Molecular Level
Brain Cell Communication at the Molecular Level Neural communication isn’t abstract, it’s a sequence of tightly regulated biophysical events. Ion gradients shift, channels open and close with millisecond precision, calcium signals trigger chemical release, and...
Astatine-211: The Alpha-Emitter Gaining Momentum in Targeted Radiotherapy
Astatine, the heaviest halogen and the rarest naturally occurring element, has long been a scientific curiosity. Among its many isotopes, ²¹¹At has emerged over the past decade as a frontrunner in the quest to harness alpha particles for highly targeted radiotherapy....
Life Science Development in Singapore: A Rising Global Powerhouse
Singapore has rapidly transformed into one of the world’s most advanced and influential life science hubs. Over the past two decades, the city-state has combined strategic investment, world-class infrastructure, and a thriving innovation ecosystem to position itself...
Halozyme Granted Injunction Against Merck in Keytruda Patent Case
A German court has granted Halozyme a preliminary injunction that halts the sale of the subcutaneous version of Keytruda in Germany, marking a significant legal win in the companies’ high stakes patent dispute. The decision could complicate Merck’s plans for the...
Pharma 5.0: The Future of Human-Centric, Intelligent, Sustainable Medicine
As the pharmaceutical industry undergoes rapid transformation, a new paradigm is taking shape. Known as Pharma 5.0, it represents more than an upgrade in technology, it is a fundamental shift toward human-centric innovation, sustainable manufacturing, and intelligent...
Pharvaris Announces Positive Phase 3 Results for Deucrictibant
Pharvaris Announces Positive Phase 3 Results for Deucrictibant as On Demand HAE Treatment Pharvaris has announced positive topline data from its global Phase 3 RAPIDe 3 study, confirming that the oral bradykinin B2 receptor antagonist deucrictibant shows strong...
AI & Cloud Enabled R&D and Clinical Operations Surge in Life Sciences
Digital transformation is accelerating across the life sciences sector as more organisations adopt AI driven platforms and cloud computing to speed up drug discovery, streamline clinical trials and optimise operations. A recent industry overview from BioSpace...
Autolus CAR-T Offers Hope to Adults with Aggressive Blood Cancer
The National Institute for Health and Care Excellence (NICE) has published final draft guidance recommending a novel, next-generation chimeric antigen receptor T-cell (CAR-T) therapy for use in the National Health Service (NHS). This landmark decision is set to...
Otsuka Wins Approval for Novel Rare Kidney Drug
Otsuka Gains Approval for First of Its Kind Treatment Against Rare Kidney Disease In a significant milestone for kidney disease care, Otsuka Pharmaceutical has received accelerated approval from the US Food and Drug Administration for a new therapy for Immunoglobulin...
US and UK Agree Zero Tariffs Deal on Pharmaceuticals
US and UK Agree Zero Tariffs Deal on Pharmaceuticals: What It Means for Patients, Innovation and Global Pharma Trade The United States and the United Kingdom have reached a landmark trade agreement that eliminates tariffs on UK-origin pharmaceuticals, active...
Hot Topic to Watch in China Life Sciences: Data Exclusivity & IP Reforms
China’s life sciences sector is poised for a potential regulatory shake-up this week, as stakeholders await clarity on data exclusivity and intellectual property (IP) protection reforms. Earlier this year, the National Medical Products Administration (NMPA) released a...
A Milestone in Rare Disease Genomics
Why popEVE Matters Interpreting missense variants has long been one of the most persistent challenges in clinical genetics. These single–amino-acid substitutions can subtly alter protein structure or function, yet their effects are often context-dependent and...
Brain Cell Communication at the Molecular Level
Brain Cell Communication at the Molecular Level Neural communication isn’t abstract, it’s a sequence of tightly regulated biophysical events. Ion gradients shift, channels open and close with millisecond precision, calcium signals trigger chemical release, and...
Featured Articles
Further News
Welcome to Life Science Daily News
Your Gateway to Discovery, Innovation, and Global Scientific Voices In a world where breakthroughs happen every day and scientific understanding is accelerating faster than ever before, Life Science Daily News stands as a vibrant hub for curious minds, passionate...
New Hope for Patients with Hereditary Hemorrhagic Telangiectasia
Engasertib Trial Offers New Hope for Patients with Hereditary Hemorrhagic Telangiectasia A recent clinical study has delivered encouraging results for people living with hereditary hemorrhagic telangiectasia, a rare genetic vascular disorder that causes chronic and...
ALS- Clinical Signals of a “Synaptic Regenerative” Approach!
Pharmaceutical approaches to ALS remain sparse and "hard-to-develop". Riluzole (approved 1995) and edaravone (IV in 2017, oral in 2022) only offer modest benefits. More recently, Biogen's Qalsody (tofersen) was approved for SOD1-mutant ALS. But a new wave of new...
Decision Frameworks in Pharma
Decision Frameworks in Pharma: From RAVE and DICE to Lilly’s Truth-Seeking Machine What Works, What Kills What, and Why It Matters In pharmaceutical R&D, where billions ride on the flip of a biological coin, decision frameworks aren’t just nice-to-haves - they’re...
Follow the Science? It Would Rather Follow a Leader… (2025 Update)
Eight years on from the first version of this article, “follow the science” is still the industry’s favourite comfort blanket. It sounds noble, unassailable, the kind of thing you put on a lab-wall poster next to a photo of Rosalind Franklin. (Following the X...
Durvalumab approved in the US
Durvalumab approved in the US as first & only perioperative immunotherapy for patients with early gastric & gastroesophageal cancers! The FDA approved Durvalumab (Imfinzi) in combination with Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel (FLOT)...
Redefining Drug Safety: Global Regulators Push for AI and 3D Tissues
For decades, the laboratory rat has been the quintessential symbol of biomedical research. Yet, as 2025 draws to a close, a profound shift is reshaping the life sciences landscape. Global regulatory bodies are no longer merely encouraging alternatives to animal...
Novartis to Acquire Avidity in $12B RNA Therapy Deal
The biotech M&A boom shows no signs of slowing. Novartis has struck a definitive agreement to acquire Avidity Biosciences for US$12 billion in cash, marking one of the most consequential acquisitions in the RNA therapy space in recent years. The deal significantly...
Ground-Breaking Gene Therapy for Hunter Syndrome
Miraculous Progress for 3-Year-Old After Ground-Breaking Gene Therapy for Hunter Syndrome A three-year-old boy, Oliver Chu, has astounded doctors after becoming the first person in the world with Hunter syndrome also called MPS II to receive a pioneering gene therapy....
UK Drug Pricing Pressure Threatens Pharma Investment and Competitiveness
The row over drug pricing in the United Kingdom has escalated into a defining test for the government’s life sciences strategy. In 2025 tensions between Whitehall and major pharmaceutical companies have hardened, with a series of high-profile investment pauses and...
AstraZeneca and Sun Pharma Join Forces in India
AstraZeneca and Sun Pharma Join Forces to Expand Access to Hyperkalaemia Treatment in India In a major development for renal and cardiac care in India, AstraZeneca Pharma India and Sun Pharmaceutical Industries have announced a strategic co-marketing partnership to...
J&J Acquires Halda Therapeutics to Boost Oncology Pipeline
Johnson & Johnson has agreed to acquire Halda Therapeutics for $3.05 billion in cash, a transaction announced on 17 November 2025 and expected to close in the coming months, subject to customary regulatory approvals. Halda’s Novel RIPTAC Modality Halda...
Further News
Want to Be Part of the Next Chapter in Life Sciences Media?
LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.
Don’t wait for the media to pick up your story. Be the media.
See More Articles
Want to Be Part of the Next Chapter in Life Sciences Media?
LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.